Achilles Common Stock Shares Outstanding vs Non Currrent Assets Other Analysis

ACHL Stock

USD 1.06 0.01 0.93%

Achilles Therapeutics financial indicator trend analysis is way more than just evaluating Achilles Therapeutics PLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Achilles Therapeutics PLC is a good investment. Please check the relationship between Achilles Therapeutics Common Stock Shares Outstanding and its Non Currrent Assets Other accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Common Stock Shares Outstanding vs Non Currrent Assets Other

Common Stock Shares Outstanding vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Achilles Therapeutics PLC Common Stock Shares Outstanding account and Non Currrent Assets Other. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Achilles Therapeutics' Common Stock Shares Outstanding and Non Currrent Assets Other is 0.95. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Achilles Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Achilles Therapeutics' Common Stock Shares Outstanding and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Achilles Therapeutics PLC are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Common Stock Shares Outstanding i.e., Achilles Therapeutics' Common Stock Shares Outstanding and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

0.95

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most indicators from Achilles Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Achilles Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

At this time, Achilles Therapeutics' Tax Provision is quite stable compared to the past year. Enterprise Value Over EBITDA is expected to rise to 1.36 this year, although the value of Issuance Of Capital Stock will most likely fall to 8,550.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	64.2M	78.4M	75.3M	58.4M
Cost Of Revenue	3.3M	3.7M	4.7M	2.8M

Total Operating Expenses Cost Of Revenue

Achilles Therapeutics fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Other Current Assets	Other Stockholder Equity	Total Current Assets	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Inventory
Other Current Liab		0.99	0.98	-0.81	0.91	0.93	0.95	0.97	0.96	0.97	0.94	0.87	0.93	0.94	-0.1	-0.9	0.92	0.95	0.98	0.92	0.96	0.93	-0.39	0.69	0.87	0.7
Total Current Liabilities	0.99		0.98	-0.83	0.96	0.94	0.92	0.98	0.96	0.98	0.91	0.89	0.89	0.95	-0.17	-0.84	0.88	0.95	0.98	0.88	0.97	0.97	-0.42	0.72	0.89	0.64
Net Tangible Assets	0.98	0.98		-0.8	0.91	0.9	0.91	0.97	0.98	0.96	0.91	0.85	0.9	0.92	-0.08	-0.87	0.89	0.92	0.95	0.89	0.94	0.91	-0.4	0.68	0.85	0.64
Retained Earnings	-0.81	-0.83	-0.8		-0.81	-0.85	-0.78	-0.89	-0.72	-0.76	-0.66	-0.58	-0.64	-0.67	0.61	0.5	-0.61	-0.69	-0.78	-0.61	-0.85	-0.86	0.77	-0.23	-0.58	-0.27
Accounts Payable	0.91	0.96	0.91	-0.81		0.87	0.8	0.92	0.87	0.96	0.79	0.88	0.75	0.9	-0.27	-0.69	0.74	0.91	0.93	0.74	0.97	0.99	-0.44	0.73	0.88	0.48
Net Receivables	0.93	0.94	0.9	-0.85	0.87		0.96	0.96	0.89	0.86	0.83	0.75	0.82	0.83	-0.37	-0.76	0.79	0.84	0.91	0.79	0.89	0.9	-0.38	0.53	0.75	0.7
Other Current Assets	0.95	0.92	0.91	-0.78	0.8	0.96		0.94	0.92	0.87	0.92	0.78	0.92	0.87	-0.16	-0.89	0.9	0.88	0.93	0.9	0.86	0.85	-0.31	0.58	0.78	0.82
Other Stockholder Equity	0.97	0.98	0.97	-0.89	0.92	0.96	0.94		0.94	0.93	0.86	0.78	0.84	0.86	-0.28	-0.79	0.82	0.88	0.93	0.82	0.96	0.93	-0.46	0.56	0.78	0.61
Total Current Assets	0.96	0.96	0.98	-0.72	0.87	0.89	0.92	0.94		0.94	0.96	0.89	0.95	0.95	0.01	-0.91	0.94	0.95	0.96	0.94	0.88	0.87	-0.34	0.73	0.89	0.72
Property Plant Equipment	0.97	0.98	0.96	-0.76	0.96	0.86	0.87	0.93	0.94		0.92	0.93	0.89	0.97	-0.04	-0.86	0.89	0.97	0.98	0.89	0.97	0.96	-0.37	0.8	0.93	0.61
Total Assets	0.94	0.91	0.91	-0.66	0.79	0.83	0.92	0.86	0.96	0.92		0.91	1.0	0.96	0.11	-0.96	1.0	0.96	0.96	1.0	0.82	0.82	-0.33	0.75	0.91	0.76
Short Long Term Debt Total	0.87	0.89	0.85	-0.58	0.88	0.75	0.78	0.78	0.89	0.93	0.91		0.89	0.98	0.11	-0.84	0.89	0.98	0.94	0.89	0.83	0.88	-0.29	0.91	1.0	0.62
Total Stockholder Equity	0.93	0.89	0.9	-0.64	0.75	0.82	0.92	0.84	0.95	0.89	1.0	0.89		0.94	0.14	-0.97	1.0	0.95	0.94	1.0	0.79	0.79	-0.31	0.73	0.89	0.78
Property Plant And Equipment Net	0.94	0.95	0.92	-0.67	0.9	0.83	0.87	0.86	0.95	0.97	0.96	0.98	0.94		0.05	-0.89	0.94	1.0	0.98	0.94	0.88	0.91	-0.34	0.85	0.98	0.68
Current Deferred Revenue	-0.1	-0.17	-0.08	0.61	-0.27	-0.37	-0.16	-0.28	0.01	-0.04	0.11	0.11	0.14	0.05		-0.31	0.18	0.03	-0.1	0.18	-0.24	-0.31	0.59	0.39	0.11	0.26
Net Debt	-0.9	-0.84	-0.87	0.5	-0.69	-0.76	-0.89	-0.79	-0.91	-0.86	-0.96	-0.84	-0.97	-0.89	-0.31		-0.97	-0.89	-0.88	-0.97	-0.75	-0.71	0.09	-0.76	-0.84	-0.86
Cash	0.92	0.88	0.89	-0.61	0.74	0.79	0.9	0.82	0.94	0.89	1.0	0.89	1.0	0.94	0.18	-0.97		0.94	0.93	1.0	0.78	0.77	-0.3	0.74	0.89	0.77
Non Current Assets Total	0.95	0.95	0.92	-0.69	0.91	0.84	0.88	0.88	0.95	0.97	0.96	0.98	0.95	1.0	0.03	-0.89	0.94		0.99	0.94	0.89	0.92	-0.35	0.84	0.98	0.68
Non Currrent Assets Other	0.98	0.98	0.95	-0.78	0.93	0.91	0.93	0.93	0.96	0.98	0.96	0.94	0.94	0.98	-0.1	-0.88	0.93	0.99		0.93	0.94	0.95	-0.4	0.76	0.94	0.68
Cash And Short Term Investments	0.92	0.88	0.89	-0.61	0.74	0.79	0.9	0.82	0.94	0.89	1.0	0.89	1.0	0.94	0.18	-0.97	1.0	0.94	0.93		0.78	0.77	-0.3	0.74	0.89	0.77
Common Stock Total Equity	0.96	0.97	0.94	-0.85	0.97	0.89	0.86	0.96	0.88	0.97	0.82	0.83	0.79	0.88	-0.24	-0.75	0.78	0.89	0.94	0.78		0.97	-0.43	0.66	0.83	0.53
Common Stock Shares Outstanding	0.93	0.97	0.91	-0.86	0.99	0.9	0.85	0.93	0.87	0.96	0.82	0.88	0.79	0.91	-0.31	-0.71	0.77	0.92	0.95	0.77	0.97		-0.49	0.69	0.88	0.5
Short Term Investments	-0.39	-0.42	-0.4	0.77	-0.44	-0.38	-0.31	-0.46	-0.34	-0.37	-0.33	-0.29	-0.31	-0.34	0.59	0.09	-0.3	-0.35	-0.4	-0.3	-0.43	-0.49		0.11	-0.29	0.27
Non Current Liabilities Total	0.69	0.72	0.68	-0.23	0.73	0.53	0.58	0.56	0.73	0.8	0.75	0.91	0.73	0.85	0.39	-0.76	0.74	0.84	0.76	0.74	0.66	0.69	0.11		0.91	0.64
Capital Lease Obligations	0.87	0.89	0.85	-0.58	0.88	0.75	0.78	0.78	0.89	0.93	0.91	1.0	0.89	0.98	0.11	-0.84	0.89	0.98	0.94	0.89	0.83	0.88	-0.29	0.91		0.62
Inventory	0.7	0.64	0.64	-0.27	0.48	0.7	0.82	0.61	0.72	0.61	0.76	0.62	0.78	0.68	0.26	-0.86	0.77	0.68	0.68	0.77	0.53	0.5	0.27	0.64	0.62

Click cells to compare fundamentals

Achilles Therapeutics Account Relationship Matchups

Achilles Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	681K	6.6M	10.9M	8.3M	7.8M	6.3M
Total Current Liabilities	3.9M	16.6M	19.1M	18.0M	17.0M	13.9M
Net Tangible Assets	101.3M	189.2M	289.5M	197.0M	226.6M	173.7M
Retained Earnings	(24.8M)	(58.0M)	(119.1M)	(190.3M)	(260.0M)	(247.0M)
Accounts Payable	902K	6.3M	3.7M	5.2M	5.6M	4.0M
Net Receivables	4.5M	7.3M	11.2M	16.0M	10.4M	9.5M
Other Current Assets	477K	2.6M	7.3M	7.2M	3.7M	4.0M
Other Stockholder Equity	118.0M	234.9M	401.9M	409.0M	415.2M	289.4M
Total Current Assets	103.1M	187.8M	284.7M	196.6M	145.6M	170.7M
Property Plant Equipment	2.1M	28.1M	28.8M	20.5M	23.6M	17.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Achilles Therapeutics PLC is a strong investment it is important to analyze Achilles Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Achilles Therapeutics' future performance. For an informed investment choice regarding Achilles Stock, refer to the following important reports:

How To Invest In Achilles

Details

Is Achilles Stock a good investment?

Details

What is Achilles Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.66)

Return On Assets

(0.27)

Return On Equity

(0.44)

The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Achilles Common Stock Shares Outstanding vs Non Currrent Assets Other Analysis

Common Stock Shares Outstanding vs Non Currrent Assets Other

Common Stock Shares Outstanding vs Non Currrent Assets Other Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Non Currrent Assets Other

Achilles Therapeutics fundamental ratios Correlations

Achilles Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Achilles Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Cash	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity

Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Net Debt	- 0.97	Total Stockholder Equity
Net Debt	- 0.96	Total Assets
Net Debt	- 0.91	Total Current Assets
Net Debt	- 0.9	Other Current Liab